Based on the latest data from August 2025, BAC is trading at $50.74, positioning the stock in the overvalued zone between the 13.4x and 15.1x PE multiples. The current price significantly exceeds the fair valuation boundary of $36.48 (10.0x PE) and surpasses the watch zone upper limit of $42.60 (11.7x PE), indicating the stock is trading at elevated valuation levels that warrant caution from investors. Analyzing the historical trend, BAC's valuation has experienced dramatic fluctuations over the past five years. The stock began 2020 in the fair value zone but crashed into undervalued territory during the March 2020 pandemic selloff, trading well below the 6.7x PE boundary. From mid-2021 through early 2022, the stock consistently traded in the overvalued and warning zones, with prices frequently exceeding $40-45. Following a correction in 2022-2023 that brought valuations back to more reasonable levels around the fair value zone, BAC has experienced another significant expansion since late 2024. The stock has moved from the fair value zone in early 2024 to currently trading in overvalued territory, suggesting investors are paying premium valuations that may limit future returns. This recent valuation expansion, combined with the stock's history of cyclical PE compression, indicates potential downside risk from current levels.